Target Name: RTL1
NCBI ID: G388015
Review Report on RTL1 Target / Biomarker Content of Review Report on RTL1 Target / Biomarker
RTL1
Other Name(s): HUR1 | Sushi-Ichi retrotransposon homolog 2 | PEG11 | paternally expressed 11 | Retrotransposon-like protein 1 | Retrotransposon-derived protein PEG11 | retrotransposon-like 1 | mammalian retrotransposon-derived 1 | Paternally expressed gene 11 protein | Retrotransposon Gag like 1 | MART1 | retrotransposon-derived protein PEG11 | RTL1_HUMAN | Mar1 | retrotransposon Gag like 1 | SIRH2 | paternally expressed gene 11 protein | Mammalian retrotransposon derived protein 1 | mammalian retrotransposon derived protein 1

Understanding RTL1: Potential Drug Target and Biomarker

RTL1 (HUR1) is a protein that is expressed in various tissues throughout the body, including the brain, spinal cord, and peripheral nerves. It is a member of the T-cell receptor (TCR) family, which is a group of proteins that are involved in cell signaling and immune responses.

While RTL1 has been identified as a potential drug target and biomarker for various diseases, including cancer, it is still a relatively little-known protein. However, research into RTL1 and its potential uses is ongoing.

One of the main functions of RTL1 is its role in the immune system. As a member of the TCR family, RTL1 is involved in the process of T-cell development and activation. It is thought to play a key role in the development of T-cell tolerance, which is the ability of the immune system to distinguish between self and non-self and avoid attacking the body's own cells.

In addition to its role in T-cell development, RTL1 is also involved in the regulation of pain and inflammation. Studies have shown that RTL1 is expressed in the pain modulatory neurons that are responsible for registering pain signals in the brain. It is also involved in the regulation of inflammation, as it has been shown to play a role in the recruitment of immune cells to the site of inflammation.

Another potential use of RTL1 as a drug target is its role in cancer. Studies have shown that RTL1 is often expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It is also thought to play a role in the development of cancer stem cells, which are cells that are capable of self-replication and have the potential to develop into fully developed cancer cells.

In addition to its potential as a cancer drug target, RTL1 has also been identified as a potential biomarker for several diseases. For example, studies have shown that RTL1 is often expressed in the brains of individuals with Alzheimer's disease, a condition that is characterized by the progressive loss of brain cells. It is also thought to be involved in the regulation of neurodegeneration, as has been shown to play a role in the development of neurodegenerative diseases.

While RTL1 is still a relatively little-known protein, research into its potential uses is ongoing. As more research is done on RTL1 and its role in the immune system and cancer, it is likely that new potential drugs and treatments will be discovered.

In conclusion, RTL1 is a protein that is expressed in various tissues throughout the body and is involved in the immune system and cancer development. While it is still a relatively little-known protein, research into its potential uses is ongoing and it is likely that new treatments and drugs will be discovered in the future.

Protein Name: Retrotransposon Gag Like 1

Functions: Plays an essential role in capillaries endothelial cells for the maintenance of feto-maternal interface and for development of the placenta

The "RTL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RTL10 | RTL3 | RTL4 | RTL5 | RTL6 | RTL8A | RTL8B | RTL8C | RTL9 | RTN1 | RTN2 | RTN3 | RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5